4.3 Review

Metaorganismal nutrient metabolism as a basis of cardiovascular disease

Journal

CURRENT OPINION IN LIPIDOLOGY
Volume 25, Issue 1, Pages 48-53

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOL.0000000000000036

Keywords

atherosclerosis; cholesterol; l-carnitine; trimethylamine; trimethylamineoxide

Funding

  1. National Institutes of Health and Office of Dietary Supplements grants [R00 HL096166, R01 HL103866, P20 HL113452, P01 HL076491, P01 HL098055]
  2. Leducq Fondation
  3. Cleveland Clinic Foundation General Clinical Research Center of the Cleveland Clinic/Case Western Reserve University CTSA [1UL1RR024989]
  4. Abbott
  5. Astra Zeneca
  6. Cleveland Heart Lab
  7. Esperion
  8. Liposciences, Inc.
  9. Procter Gamble
  10. Takeda

Ask authors/readers for more resources

Purpose of reviewAtherosclerosis and associated cardiovascular disease (CVD) remains the leading cause of mortality in Western societies. It is well accepted that the consumption of foods abundant in saturated fats and cholesterol, like meats, egg yolk and high-fat dairy products, are associated with increased CVD risk. New evidence suggests that trimethylamine (TMA)-containing nutrients within these foods, including phosphatidylcholine, choline, and l-carnitine, can enter into a microbial metabolic pathway that promotes CVD. In this review, we highlight the role of gut microbiota-driven nutrient metabolism as a novel pathway promoting CVD.Recent findingsRecent studies demonstrate a link between ingestion of dietary phosphatidylcholine, choline, and l-carnitine and CVD risk. At the center of this pathway is gut microbiota-dependent synthesis of a metabolic intermediate called TMA, and subsequent host-driven conversion of TMA to trimethylamine-N-oxide (TMAO). Microbiota-dependent generation of TMAO is associated with increased risk of incident major adverse cardiovascular events in humans, and provision of TMAO promotes atherosclerosis in mice.SummaryMicrobial metabolism of TMA containing nutrients can lead to formation of the proatherogenic compound TMAO. Recent insights into this diet-microbe-host interaction provide new clues surrounding the pathogenesis of atherosclerosis, and may serve as a framework for new CVD therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available